|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/7076 | (2006.01) |
| A61P 21/04 | (2006.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 3654989 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18739593.4 |
| Date of filing the European patent application | 2018-06-28 | |
| (97) | Date of publication of the European application | 2020-05-27 |
| (45) | Date of publication and mention of the grant of the patent | 2024-01-03 |
| (46) | Date of publication of the claims translation | 2024-03-25 |
| (86) | Number | PCT/GB2018/051801 |
| Date | 2018-06-28 |
| (87) | Number | WO 2019/016505 |
| Date | 2019-01-24 |
| (30) | Number | Date | Country code |
| 201711800 | 2017-07-21 | GB |
| (72) |
REJDAK, Konrad , PL
|
| (73) |
Chord Therapeutics SA ,
c/o ARES TRADING SA
Terre Bonne Business Park
Route de Crassier 1, 1262 Eysins,
CH
|
| (74) |
Marija LENKUTIENĖ,
Patentinių paslaugų centras, UAB, Jono Basanavičiaus g. 11/1, LT-03108 Vilnius,
LT
|
| (54) | Kladribino panaudojimas autoimuninės neuromuskulinės ligos gydymui |
| USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASE |
| Payment date | Validity (years) | Amount | |
| 2025-05-20 | 8 | 185.00 EUR |
| 2026-06-28 |